Udai Banerji

Fulham Road
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 128 publications

Phase I safety, efficacy, and biomarker response evaluations of three oral PD-L1 inhibitors: INCB086550, INCB099280, and INCB099318.

Phase I safety, efficacy, and biomarker response evaluations of three oral PD-L1 inhibitors: INCB086550, INCB099280, and INCB099318.

Journal: Journal for immunotherapy of cancer
Published: July 27, 2026

Safety and Efficacy of HexaBody-DR5/DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity.

Safety and Efficacy of HexaBody-DR5/DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity.

Journal: Clinical and translational science
Published: November 24, 2025

Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma.

Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 24, 2025

Proteomic Landscapes of 3D and 2D Models of High-Grade Serous Ovarian Carcinoma: Implications for Carboplatin Response.

Proteomic Landscapes of 3D and 2D Models of High-Grade Serous Ovarian Carcinoma: Implications for Carboplatin Response.

Journal: Journal of proteome research
Published: August 27, 2025

Corrigendum to 'Robotic MRI/CT Guided Multiregional 'smart' Biopsy for Characterization of Tumor Heterogeneity: A Prospective Development Study' [Acad Radiol 32/2 (2025) 1100-1107].

Corrigendum to 'Robotic MRI/CT Guided Multiregional 'smart' Biopsy for Characterization of Tumor Heterogeneity: A Prospective Development Study' [Acad Radiol 32/2 (2025) 1100-1107].

Journal: Academic radiology
Published: July 12, 2025

An enzyme-free alcohol-based organoid harvesting solution.

An enzyme-free alcohol-based organoid harvesting solution.

Journal: BioTechniques
Published: July 11, 2025

Virtual Tumors Enable Prediction of Personalized Therapeutic Combinations for Non-Small Cell Lung Cancer.

Virtual Tumors Enable Prediction of Personalized Therapeutic Combinations for Non-Small Cell Lung Cancer.

Journal: Cancer research
Published: June 22, 2025

Treatment-related adverse events of antibody drug-conjugates in clinical trials.

Treatment-related adverse events of antibody drug-conjugates in clinical trials.

Journal: Journal of hematology & oncology
Published: March 05, 2025

A retrospective study of the impact of comorbidity, polypharmacy and demographic factors on patient inclusion and healthcare delivery in phase I oncology trials.

A retrospective study of the impact of comorbidity, polypharmacy and demographic factors on patient inclusion and healthcare delivery in phase I oncology trials.

Journal: BJC reports
Published: January 28, 2025

Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial.

Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial.

Journal: Nature medicine
Published: December 12, 2024

Tumor control and immune activation through palliative irradiation and ATR inhibition, PATRIOT Part C: a phase Ib trial.

Tumor control and immune activation through palliative irradiation and ATR inhibition, PATRIOT Part C: a phase Ib trial.

Journal: Nature communications
Published: October 31, 2024

Corrigendum to "Unbiased differential proteomic profiling between cancer-associated fibroblasts and cancer cell lines" [Journal of Proteomics (2023) Volume 288, Article number 104973].

Corrigendum to "Unbiased differential proteomic profiling between cancer-associated fibroblasts and cancer cell lines" [Journal of Proteomics (2023) Volume 288, Article number 104973].

Journal: Journal of proteomics
Published: September 07, 2024
Showing 1-12 of 128

Last Updated: 09/26/2026